Newsroom | 8658 results
Sorted by: Latest
-
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference, in New York, New York. Management is scheduled to present on Thursday, November 13, 2025, at 2:40 pm ET. Piper Sandler 37th Annual Healthcare Conference, in New York, New Yor...
-
Family Heart Foundation® to Present Key Findings and Data on Genetic Dyslipidemias at the 2025 American Heart Association Scientific Sessions
NEW ORLEANS--(BUSINESS WIRE)--Family Heart Foundation presents research findings and data focused on genetic dyslipidemias at the AHA Scientific Sessions 2025....
-
Cardiosense Presents New Analysis of the SEISMIC-HF I Study Validating its AI Algorithm for Noninvasive PCWP Assessment at the American Heart Association's 2025 Scientific Sessions
CHICAGO--(BUSINESS WIRE)--Cardiosense, a digital health company pioneering AI-enabled solutions for cardiac disease management, today announced a secondary analysis from the SEISMIC-HF I study on the performance of an AI algorithm for noninvasive congestion assessment at the point of care. The new analysis will be presented by Marat Fudim, MD, Associate Professor of Medicine at Duke University Health System, as a moderated poster session at the American Heart Association's (AHA) 2025 Scientific...
-
Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the third quarter ended September 30, 2025. Recent Business Highlights Soft Tissue Ablation Initiated a multi-center clinical study, PRECISE-BTN, for the treatment of benign thyroid nodules (BTN) with the nPulse Vybrance perc...
-
First in Human Ischemic VT Ablation Successfully Performed in iCMR
MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), together with Amsterdam University Medical Centre (Amsterdam UMC), is pleased to announce the successful completion of the first Ischemic Ventricular Tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab. The Amsterdam UMC team, shown here, performed the VT ablation procedure following previous experiences performing atrial flutter and premature ventricular complex (PVC) a...
-
Samenvatting: Eerste ischemische VT-ablatie bij mensen met succes uitgevoerd in iCMR
MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. (het Bedrijf of Imricor) (ASX: IMR), kondigt samen met het Amsterdam Universitair Medisch Centrum (Amsterdam UMC) met genoegen de geslaagde voltooiing aan van de eerst ischemische VT-ablatie (ventriculaire tachycardie) die ooit onder realtime MRI-begeleiding in een iCMR-labo werd uitgevoerd. Het team van het Amsterdam UMC, hier te zien, voerde de VT-ablatieprocedure uit na eerdere ervaringen opgedaan tijdens het uitvoeren van ablatiepr...
-
Resumen: Realizan con éxito la primera ablación de taquicardia ventricular isquémica en humanos realizada en iCMR
MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. (Company o Imricor) (ASX: IMR), conjuntamente con el Centro Médico Universitario de Ámsterdam (Amsterdam UMC), se complace en anunciar el éxito de la primera ablación de taquicardia ventricular isquémica (TV), asistida por resonancia magnética en tiempo real en un laboratorio iCMR. El equipo del Amsterdam UMC, que aparece en la imagen, fue el encargado de realizar el procedimiento de ablación de TV tras haber realizado otros procedimie...
-
Riassunto: Eseguito con successo il primo intervento di ablazione della TV ischemica in un paziente umano con iCMR
MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. (Società o Imricor) (ASX: IMR), insieme all'Amsterdam University Medical Centre (Amsterdam UMC), è lieta di annunciare la conclusione riuscita del primo intervento di ablazione della tachicardia ventricolare (TV) ischemica guidato da RMN in tempo reale mai eseguito in un laboratorio di iCMR (risonanza magnetica cardiaca guidata). Il team del Centro medico universitario di Amsterdam, illustrato qui, ha eseguito l'intervento di ablazione...
-
Première ablation réussie d’une TV ischémique chez l’homme réalisée dans un laboratoire iCMR
MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. (la société ou Imricor) (ASX : IMR), en collaboration avec le Centre médical universitaire d’Amsterdam (Amsterdam UMC), a le plaisir d’annoncer la réussite de la première ablation d’une tachycardie ventriculaire (TV) ischémique jamais réalisée sous guidage IRM en temps réel dans un laboratoire iCMR. L’équipe de l’Amsterdam UMC, présentée ici, a réalisé la procédure d’ablation de la TV après avoir déjà effectué des procédures d’ablation...
-
Erstmalig am Menschen durchgeführte VT-Ablation in der iCMR erfolgreich
MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. ( das Unternehmen bzw.Imricor ) ( ASX: IMR ) gibt gemeinsam mit dem Medizinischen Zentrum der Universität Amsterdam (Amsterdam UMC) erfreut bekannt, dass die erstmals mit MRT-Unterstützung in Echtzeit in einem iCMR-Labor durchgeführte ischämische Ventrikel-Tachykardie- (VT)-Ablation erfolgreich verlaufen ist. Das hier abgebildete Team des Amsterdam UMC führte die VT-Ablation durch, nachdem zuvor Erfahrungen mit Ablationsverfahren für V...